Meeting
2020 ASCO Virtual Scientific Program
Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory diffuse large B-cell Lymphomas (R/R DLBCL): Primary analysis of a phase II trial from LYSA.
Presenter
Charles Herbaux, MD, MSc
Centre Hospitalier Régional Universitaire de Lille, Institute of Hematolog-Tranfusion
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT03276468
Citation
J Clin Oncol 38: 2020 (suppl; abstr 8053)
DOI
10.1200/JCO.2020.38.15_suppl.8053
Abstract #
8053
Poster Bd #
386
Abstract Disclosures
Similar Videos & Slides
Speaker: Panel Discussion
Videos & Slides
2021 ASCO Annual Meeting
Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory indolent non-Hodgkin’s lymphoma (R/R iNHL): Primary analysis of a phase 2 trial from LYSA.
Speaker: Charles Herbaux, MD, MSc
Videos & Slides
2024 ASCO Annual Meeting
Epcoritamab + R-DHAX/C in transplant-eligible patients (pts) with high-risk relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Speaker: Yasmin Karimi, MD
Videos & Slides
2024 ASCO Annual Meeting
Carfilzomib plus rituximab, ifosfamide, carboplatin and etoposide (C-RICE) led to higher response, OS, and PFS in patients with transplant-eligible relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Speaker: Mody Amin, MD, DO